Short answer
Idexx Laboratories (IDXX) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results announced May 5, 2026, covering IDEXX Laboratories’ first fiscal quarter.
Idexx Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results announced May 5, 2026, covering IDEXX Laboratories’ first fiscal quarter
- Detailed financial results and management commentary available in Exhibit 99.1 press release
- Filing signed by CFO and Treasurer Andrew Emerson
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $1,141M, up 14% reported and 11% organic, led by CAG Diagnostics recurring revenue growth of 14% reported and 11% organic
- EPS $3.47, up 17% reported and 15% comparable, with operating margin reaching 31.8%
- 2026 revenue guidance raised to $4,675M-$4,760M, increasing midpoint by $42M on stronger recurring diagnostics performance
- 2026 EPS outlook increased to $14.45-$14.90, up $0.13 at midpoint, supported by revenue and comparable margin improvements
- IDEXX inVue Dx placements reached 1,100, while CAG Diagnostics capital instrument revenue rose 33% reported and 28% organic
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Idexx Laboratories 8-K filings
Get the next IDXX 8-K as it lands
Follow IDXX for push alerts, or ask the research agent what this filing means.